107 related articles for article (PubMed ID: 29915948)
1. Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study.
Jerzak KJ; Cockburn JG; Dhesy-Thind SK; Pond GR; Pritchard KI; Nofech-Mozes S; Sun P; Narod SA; Bane A
Breast Cancer Res Treat; 2018 Oct; 171(3):709-717. PubMed ID: 29915948
[TBL] [Abstract][Full Text] [Related]
2. Thyroid hormone receptor (TR)alpha and TRbeta expression in breast cancer.
Ditsch N; Toth B; Himsl I; Lenhard M; Ochsenkühn R; Friese K; Mayr D; Jeschke U
Histol Histopathol; 2013 Feb; 28(2):227-37. PubMed ID: 23275305
[TBL] [Abstract][Full Text] [Related]
3. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2017 Sep; 165(2):391-402. PubMed ID: 28601929
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor expression and breast cancer mortality in a population-based prospective cohort.
Elebro K; Bendahl PO; Jernström H; Borgquist S
Breast Cancer Res Treat; 2017 Oct; 165(3):645-657. PubMed ID: 28643022
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
6. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
10. The relationship between local recurrence and death in early-stage breast cancer.
Sopik V; Nofech-Mozes S; Sun P; Narod SA
Breast Cancer Res Treat; 2016 Jan; 155(1):175-85. PubMed ID: 26712515
[TBL] [Abstract][Full Text] [Related]
11. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
[TBL] [Abstract][Full Text] [Related]
12. Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival.
Pelkonen M; Luostari K; Tengström M; Ahonen H; Berdel B; Kataja V; Soini Y; Kosma VM; Mannermaa A
BMC Cancer; 2015 May; 15():431. PubMed ID: 26014348
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
14. 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.
Turashvili G; Chou JF; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
Breast Cancer Res Treat; 2017 Nov; 166(1):69-76. PubMed ID: 28702894
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.
Curtit E; Pivot X; Henriques J; Paget-Bailly S; Fumoleau P; Rios M; Bonnefoi H; Bachelot T; Soulié P; Jouannaud C; Bourgeois H; Petit T; Tennevet I; Assouline D; Mathieu MC; Jacquin JP; Lavau-Denes S; Darut-Jouve A; Ferrero JM; Tarpin C; Lévy C; Delecroix V; Trillet-Lenoir V; Cojocarasu O; Meunier J; Pierga JY; Kerbrat P; Faure-Mercier C; Blanché H; Sahbatou M; Boland A; Bacq D; Besse C; Thomas G; Deleuze JF; Pauporté I; Romieu G; Cox DG
Breast Cancer Res; 2017 Aug; 19(1):98. PubMed ID: 28830573
[TBL] [Abstract][Full Text] [Related]
17. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
[TBL] [Abstract][Full Text] [Related]
18. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
19. Tumor characteristics and prognosis in familial breast cancer.
Arpino G; Pensabene M; Condello C; Ruocco R; Cerillo I; Lauria R; Forestieri V; Giuliano M; De Angelis C; Montella M; Crispo A; De Placido S
BMC Cancer; 2016 Nov; 16(1):924. PubMed ID: 27899083
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
